On April 7, 2014 Sequenom, Inc., (the "Company") received favorable decisions
from the U.S. Patent and Trademark Office, Patent Trial and Appeal Board
("PTAB") in connection with four patent interference proceedings involving the
use of DNA sequencing for noninvasive prenatal testing for Down syndrome and
other chromosomal abnormalities.

An interference is conducted by the PTAB when opposing parties have applied for
a patent to the same invention. The interference is conducted to determine which
party was the first to invent the subject matter of the interference.

The interferences which are the subject of this current report involve patent
applications which are exclusively licensed to the Company by the Chinese
University of Hong Kong, on which Dr. Dennis Lo is the first named inventor (the
"Lo Patent Applications") versus patents and a patent application which are
licensed by Stanford University ("Stanford") to Verinata Health, Inc.
("Verinata"), a wholly owned subsidiary of Illumina, Inc., on which Dr. Stephen
Quake is a named inventor (the "Quake Patents" and "Quake Patent Application").

The Quake Patents have been asserted by Verinata against the Company in a patent
infringement lawsuit filed in the United States District Court for the Northern
District of California, case no. C-12-00865 SI (the "N.D. Cal. Action").

920 Interference

In Interference No. 105,920, the PTAB concluded that Quake U.S. Patent No.
8,008,018 (the "Quake 018 Patent") lacked sufficient disclosure to meet the
written description test for the patent claims. On that basis, the PTAB entered
judgment canceling all four claims of the Quake 018 Patent and ending the
interference, thus determining that Quake is not entitled to a patent on the
subject matter of this interference.

The Company intends to bring the PTAB judgment canceling all claims of the Quake
018 Patent to the attention of the Court in the N.D. Cal. Action, where the
patent has been asserted against the Company. The Company also believes that the
PTAB's decision in the 920 Interference is relevant to Quake U.S. Patent No.
7,888,017 (the "Quake 017 Patent"). The Quake 017 Patent is also asserted
against the Company in the N.D. Cal. Action and is based upon the same
disclosure as the Quake 018 Patent.

923 and 924 Interferences

In Interference Nos. 105,923 and 105,924, the PTAB concluded that the involved
Quake Patent Application lacked sufficient disclosure to meet the written
description test for the Quake Patent Application claims. On that basis, the
PTAB refused the Quake Patent Application's claims and entered judgment ending
both interferences, thus determining that Quake is not entitled to patents on
the subject matter of the interferences.

As a result of the PTAB judgments in the 920, 923, and 924 Interferences, the
Company believes that several patents should issue from the Lo Patent
Applications which were involved in those interferences. The PTAB's decisions
may be appealed to United States District Court or the United States Court of
Appeals for the Federal Circuit. If the PTAB's decisions are appealed, further
action by the PTO with respect to the Lo Patent Applications involved in the
interferences may be delayed. The Company cannot predict the final outcome of
these matters and there can be no assurance that the final outcome of the
matters will be favorable to the Company.

922 Interference

In Interference No. 105,922 (the "922 Interference"), the PTAB determined that
the Lo U.S. Patent Application No. 13/070,266 (the "Lo 266 Application") has
sufficient disclosure to meet the written description test for the Lo 266 Patent
Application claims. The 922 Interference also involves Quake U.S. Patent No.
8,195,415 (the "Quake 415 Patent"), asserted by Verinata against the Company in
the N.D. Cal. Action. The PTAB ordered the 922 Interference to proceed to the
priority phase to determine which party (Lo or Quake) was the first to invent
the subject matter of the interference. The inventors named on the Lo 266
Application were previously declared the senior party in the 922 Interference
and are therefore presumed to be the first to invent, and entitled to a patent,
on the invention that is the subject matter of the interference. In the priority
phase, the inventors named in the Quake 415 Patent may seek to overcome that
presumption and attempt to prove they invented the subject matter of the
interference first.

2.

The Company also is separately challenging the validity of the Quake 415 Patent
in an inter partes review proceeding currently pending before the PTAB (Case IPR
013-00390).

The Company cannot predict the final outcome of the 922 Interference or the
inter partes review and there can be no assurance that the final outcome of
either matter will be favorable to the Company.

This current report contains forward-looking statements, including, but not
limited to, statements related to future activity in, and the potential outcome
of, the ongoing patent prosecution and litigation matters that are the subject
of this current report and related matters. These forward-looking statements are
based on the Company's current expectations and inherently involve significant
risks and uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result
of these risks and uncertainties, which include, without limitation, risks and
uncertainties associated with the ongoing patent prosecution and litigation
matters and the Company's ability to protect its intellectual property rights,
as detailed under the caption "Risk Factors" and elsewhere in the Company's
Securities and Exchange Commission filings and reports, including in the Annual
Report on Form 10-K for the period ended December 31, 2013 and future filings
and reports by the Company. The Company undertakes no duty or obligation to
update any forward-looking statements contained in this report as a result of
new information, future events or changes in its expectations.